Keratoacanthoma or cutaneous squamous cell carcinoma revealing a DNA mismatch repair default (Muir‐Torre Syndrome). (2nd December 2021)

• Record Type: Journal Article
• Authors: Miao, Y.; Kolb, F.; Tomasic, G.; Lupu, J.; Routier, E.; Robert, C.
• Is Part Of: Journal of the European Academy of Dermatology and Venereology. Volume 36:Number 1(2022)Supplement
• Page Start: 74
• Page End: 76
• Publication Date: 2021-12-02
• Subjects: Dermatology -- Periodicals; Sexually transmitted diseases -- Periodicals; 616.5
• DOI: 10.1111/jdv.17399
• Languages: English
• ISSNs: 0926-9959

Abstract

Abstract: Keratoacanthoma (KA) and well‐differentiated cutaneous squamous cell carcinoma (cSCC) are hardly distinguishable clinically and histologically. They both can be seen in patients with hereditary non‐polyposis colorectal cancer (HNPCC) or Lynch Syndrome, corresponding to DNA microsatellite instability. In our case, a young man had the excision of two rapidly growing skin tumours for which distinction between KA and cSCC was initially clinically and pathologically challenging. The diagnosis of well‐differentiated cSCCs was made and the patient was treated with surgery. Ten years after the first cSCC, he was diagnosed with Muir‐Torre syndrome, a variant of Lynch syndrome, with an heterozygote mutation of the MSH2 gene. This later diagnosis allowed to screen his family members for the same mutation and to adopt an appropriate follow‐up regarding the risk of digestive tumours for him and his family. Furthermore, it is important to know that, in case of non‐resectable cSCC occurring in this patient, immunotherapy using anti‐PD1 antibody would probably be effective due to the known increased immunogenicity of MMR deficient tumours.